Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| oligodendrocyte precursor cell | 10 studies | 38% ± 17% | |
| glutamatergic neuron | 8 studies | 40% ± 25% | |
| GABAergic neuron | 6 studies | 48% ± 21% | |
| neuron | 4 studies | 32% ± 13% | |
| interneuron | 4 studies | 52% ± 25% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 7 studies | 32% ± 23% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 87% | 642.36 | 2291 / 2642 | 96% | 9.86 | 677 / 705 |
| kidney | 1% | 2.26 | 1 / 89 | 52% | 4.23 | 465 / 901 |
| adrenal gland | 2% | 2.44 | 5 / 258 | 46% | 2.98 | 105 / 230 |
| bladder | 24% | 36.52 | 5 / 21 | 2% | 0.04 | 8 / 504 |
| skin | 0% | 0.24 | 2 / 1809 | 14% | 0.74 | 66 / 472 |
| pancreas | 1% | 0.61 | 2 / 328 | 13% | 0.53 | 24 / 178 |
| intestine | 12% | 15.11 | 113 / 966 | 1% | 0.04 | 6 / 527 |
| uterus | 1% | 0.47 | 1 / 170 | 3% | 0.10 | 16 / 459 |
| breast | 0% | 0 | 0 / 459 | 4% | 0.06 | 41 / 1118 |
| lung | 2% | 1.79 | 10 / 578 | 1% | 0.04 | 15 / 1155 |
| stomach | 2% | 2.33 | 8 / 359 | 1% | 0.01 | 2 / 286 |
| eye | 0% | 0 | 0 / 0 | 1% | 0.02 | 1 / 80 |
| liver | 0% | 0 | 0 / 226 | 1% | 0.04 | 3 / 406 |
| esophagus | 0% | 0 | 0 / 1445 | 1% | 0.01 | 1 / 183 |
| prostate | 0% | 0.52 | 1 / 245 | 0% | 0 | 0 / 502 |
| ovary | 0% | 0 | 0 / 180 | 0% | 0.00 | 1 / 430 |
| thymus | 0% | 0 | 0 / 653 | 0% | 0.00 | 1 / 605 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| adipose | 0% | 0 | 0 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 0% | 0 | 0 / 1335 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| heart | 0% | 0 | 0 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0007165 | Biological process | signal transduction |
| GO_0006644 | Biological process | phospholipid metabolic process |
| GO_0051491 | Biological process | positive regulation of filopodium assembly |
| GO_0046839 | Biological process | phospholipid dephosphorylation |
| GO_0010976 | Biological process | positive regulation of neuron projection development |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0008195 | Molecular function | phosphatidate phosphatase activity |
| Gene name | PLPPR5 |
| Protein name | Phospholipid phosphatase related 5 Phospholipid phosphatase-related protein type 5 (Lipid phosphate phosphatase-related protein type 5) (Phosphatidic acid phosphatase type 2d) (Plasticity-related gene 5 protein) (PRG-5) |
| Synonyms | PAP2D LPPR5 PRG5 |
| Description | FUNCTION: Induces filopodia formation and promotes neurite growth in a CDC42-independent manner; impedes neurite growth inhibitory-mediated axonal retraction. . |
| Accessions | A0A8Q3SIM6 ENST00000696571.1 Q32ZL2 A0A5F9ZI76 ENST00000370188.7 [Q32ZL2-2] ENST00000672681.1 ENST00000263177.5 [Q32ZL2-1] |